FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 01/2024”. The Monitor is a month-to-month revealed overview of enterprise capital traits within the European Healthcare & Life Sciences sector.
As of the tip of January 2024 we determine the next present VC traits in Europe:
- In January, general Life Sciences funding has reached EUR 1,087m
- Biotech acquired 62% of the overall funding quantity (EUR 675m)
- Oncology dominates as the highest indication in Biotech
- Apollo Therapeutics (United Kingdom) has the best transaction quantity of EUR 238m in January, adopted by Calluna Pharma (Norway) with EUR 75m and Timeline (Switzerland) with EUR 60m
- M&G Investments (United Kingdom) is essentially the most dominant investor (by deal quantity), adopted by Affected person Sq. Capital (United States) and Rock Springs Capital (United States)
- In January 2024, we observe a big uptake in funding volumes vs final yr (EUR 1,087m vs. EUR 576m)
To entry the total report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink.